CombiRx trial recruiting people with MS.Are combinations of the MS disease-modifying drugs more effective than taking a single drug? In 2001, a small pilot trial of Avonex (interferon interferon (ĭn'tərfēr`ŏn), any of a group of proteins produced by cells in the body in response to an attack by a virus. A cell infected by a virus releases minute amounts of interferons, which attach themselves to neighboring cells, beta- 1a) taken with Copaxone (glatiramer acetate glatiramer acetate (glahtear´a-meer as´  tāt),n a medication used to decrease or stop a relapse of multiple sclerosis. ) suggested that the combination was safe for people with relapsing relapsing /re·laps·ing/ (re-lap´sing) (re´lap-sing) recurrent; denoting an illness that is characterized by periods of remission alternating with attacks of symptomatic disease. forms of MS. Now the pilot investigators, led by Dr. Fred Lublin of the Corinne Goldsmith Dickinson Multiple Sclerosis Center at Mount Sinai School of Medicine
Mount Sinai School of Medicine is a medical school found in the borough of Manhattan in New York City. in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. , are launching a fullscale, phase 3 trial, called CombiRx, to verify the smaller study and determine the effectiveness of this combination. The trial is funded by the National Institutes of Health. People with MS sought Men and women 18-60 years of age with relapsing-remitting MS who have experienced at least two relapses in the previous three years and have never taken a disease-modifying agent are needed as study volunteers. The 36-month study will be conducted at some 80 U.S. and Canadian centers. All participants will receive at least one active medication. For specific contact information and further details of the trial, please visit nationalmssociety.org/Trials-multicenter.asp. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion